Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy
HER2-positive breast cancer is a unique subtype of the disease, not only in terms of aggressive biology, but also in terms of treatment options. Over the past 15 years, the strategy for treating early HER2-positive breast cancer has undergone a real evolution – from the absence of anti-HER2 therapy...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-01-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/766 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399144510128128 |
|---|---|
| author | I. V. Kolyadina I. V. Poddubnaya |
| author_facet | I. V. Kolyadina I. V. Poddubnaya |
| author_sort | I. V. Kolyadina |
| collection | DOAJ |
| description | HER2-positive breast cancer is a unique subtype of the disease, not only in terms of aggressive biology, but also in terms of treatment options. Over the past 15 years, the strategy for treating early HER2-positive breast cancer has undergone a real evolution – from the absence of anti-HER2 therapy to the sequential introduction of adjuvant, neoadjuvant and post neoadjuvant approaches. This review describes key studies of systemic therapy for HER2-positive breast cancer stage I–III, which made it possible to establish clear priorities in the sequence of surgical and systemic steps, identify high risk groups which need of escalation of treatment, and determine the optimal anti-HER2 therapy for each steps, as well as de-escalation of stage I treatment without losing its effectiveness. The news from the latest cancer conferences (SABCS, ESMO, ASCO) on the impact of various biological markers on the effectiveness of anti-HER2 agents is presented. A clear concept of modern treatment of early HER2-positive breast cancer has been formed, allowing individualized approaches, and achieving better results of the therapy this aggressive biological subtype. |
| format | Article |
| id | doaj-art-5dffac5ff44547f3b26d5cc0c6f2e57b |
| institution | Kabale University |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2021-01-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-5dffac5ff44547f3b26d5cc0c6f2e57b2025-08-20T03:38:24ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272021-01-01163465610.17650/1994-4098-2020-16-3-46-55658Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapyI. V. Kolyadina0I. V. Poddubnaya1Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia; V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaRussian Medical Academy of Postgraduate Education, Ministry of Health of RussiaHER2-positive breast cancer is a unique subtype of the disease, not only in terms of aggressive biology, but also in terms of treatment options. Over the past 15 years, the strategy for treating early HER2-positive breast cancer has undergone a real evolution – from the absence of anti-HER2 therapy to the sequential introduction of adjuvant, neoadjuvant and post neoadjuvant approaches. This review describes key studies of systemic therapy for HER2-positive breast cancer stage I–III, which made it possible to establish clear priorities in the sequence of surgical and systemic steps, identify high risk groups which need of escalation of treatment, and determine the optimal anti-HER2 therapy for each steps, as well as de-escalation of stage I treatment without losing its effectiveness. The news from the latest cancer conferences (SABCS, ESMO, ASCO) on the impact of various biological markers on the effectiveness of anti-HER2 agents is presented. A clear concept of modern treatment of early HER2-positive breast cancer has been formed, allowing individualized approaches, and achieving better results of the therapy this aggressive biological subtype.https://ojrs.abvpress.ru/ojrs/article/view/766early her2-positive breast cancer stage i–iiiadjuvant anti-her2 therapyneoadjuvant therapyt-dm1 in post neoadjuvant therapypredictors of anti-her2 therapy efficacypcrescalation and de-escalation of treatment |
| spellingShingle | I. V. Kolyadina I. V. Poddubnaya Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy Опухоли женской репродуктивной системы early her2-positive breast cancer stage i–iii adjuvant anti-her2 therapy neoadjuvant therapy t-dm1 in post neoadjuvant therapy predictors of anti-her2 therapy efficacy pcr escalation and de-escalation of treatment |
| title | Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy |
| title_full | Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy |
| title_fullStr | Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy |
| title_full_unstemmed | Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy |
| title_short | Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy |
| title_sort | key studies that have changed the history and treatment of early her2 breast cancer focus on individual therapy |
| topic | early her2-positive breast cancer stage i–iii adjuvant anti-her2 therapy neoadjuvant therapy t-dm1 in post neoadjuvant therapy predictors of anti-her2 therapy efficacy pcr escalation and de-escalation of treatment |
| url | https://ojrs.abvpress.ru/ojrs/article/view/766 |
| work_keys_str_mv | AT ivkolyadina keystudiesthathavechangedthehistoryandtreatmentofearlyher2breastcancerfocusonindividualtherapy AT ivpoddubnaya keystudiesthathavechangedthehistoryandtreatmentofearlyher2breastcancerfocusonindividualtherapy |